• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, August 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Frequency and outcomes of new suspicious lesions on breast MRI in neoadjuvant therapy

Bioengineer by Bioengineer
May 7, 2019
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Results to be exhibited at 2019 ARRS Annual Meeting

Leesburg, VA, May 7, 2019–During neoadjuvant chemotherapy, new suspicious findings detected on breast magnetic resonance imaging (MRI) during neoadjuvant therapy are most likely benign, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, HI.

The study was conducted to determine the frequency and outcomes of new suspicious lesions on breast MRI arising during neoadjuvant chemotherapy.

A retrospective database review found a total of 419 breast MRI examinations performed in 297 women to evaluate response to neoadjuvant chemotherapy. After exclusions for reasons including a lack of baseline pretreatment MRI for comparison, the final study cohort consisted of 28 MRI examinations (7%) with new suspicious findings.

All cases included in the study were assessed as BI-RADS 4. Twenty-five cases had either tissue diagnosis or adequate imaging follow-up to establish a diagnosis of the new suspicious findings on breast MRI. Of these 25 cases, 44% were proven benign at percutaneous biopsy, 20% at surgical pathology, and 36% were assessed benign based on follow-up imaging of 2 years or longer. That is, for all 25 cases the cancer yield for new suspicious lesions was 0%.

Results suggest that new suspicious finding on breast MRI which occur during neoadjuvant therapy are highly unlikely to signify a new malignancy, although the authors encourage further study to confirm whether biopsy may be safely avoided in these circumstances.

“We found that new suspicious lesions on MRI are not rare, occurring 7% of the time,” Donna Eckstein, MD, author of the study said. “Nearly all of these new lesions arose while the index tumor showed treatment response on MRI, and none of these new lesions were malignant. Larger studies across facilities are needed to confirm whether biopsy may be safely averted in these scenarios.”

###

With educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2019 Annual Meeting, May 5-10, at the Hawaii Convention Center in Honolulu, Hawaii. For more information, visit: http://www.arrs.org/am19.

Media Contact
Alycia Tessean
[email protected]
https://arrs.org/ARRSLIVE/Pressroom/PressReleases/neoadjuvant-therapy-lesions-breast-mri.aspx

Tags: Breast CancercancerDiagnosticsHealth Care Systems/ServicesHealth ProfessionalsMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Lipid droplet signatures classify liver cancer and reveal PLIN3 therapeutic potential

August 15, 2026

4D-Printed Breast Cancer Model Mimics Ducts, Revealing Treatment Resistance

August 15, 2026

Monocyte-derived IL-1β/p65/KRT7/ILK pathway drives epithelial–mesenchymal transition in colorectal cancer

August 15, 2026

DKMS Opens John Hansen Grant: Nearly €1 Million for Blood Cancer Research

August 15, 2026
Please login to join discussion

POPULAR NEWS

  • KAIST develops semiconductor neuron that harnesses noise to selectively process signals

    29 shares
    Share 12 Tweet 7
  • Imagining natural and extra robotic thumbs together strengthens kinesthetic sensorimotor networks

    29 shares
    Share 12 Tweet 7
  • PARP1 Drives Neuropathic Pain Through GPX4-Dependent Ferroptosis in Injured Mice’s Sensory Neurons

    29 shares
    Share 12 Tweet 7
  • Strubbelig–NHL3 Receptor Complex Helps Arabidopsis Respond to Cellulose Deficiency

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

KAIST develops semiconductor neuron that harnesses noise to selectively process signals

Imagining natural and extra robotic thumbs together strengthens kinesthetic sensorimotor networks

PARP1 Drives Neuropathic Pain Through GPX4-Dependent Ferroptosis in Injured Mice’s Sensory Neurons

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.